These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33144848)

  • 1. Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.
    Carosi G; Guabello G; Longhi M; Grifoni F; Passeri E; Corbetta S
    Mediators Inflamm; 2020; 2020():5785378. PubMed ID: 33144848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.
    Quintás-Cardama A; Sever M; Cortes J; Kantarjian H; Verstovsek S
    Leuk Lymphoma; 2013 Sep; 54(9):1959-64. PubMed ID: 23278641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.
    Sperr WR; Jordan JH; Fiegl M; Escribano L; Bellas C; Dirnhofer S; Semper H; Simonitsch-Klupp I; Horny HP; Valent P
    Int Arch Allergy Immunol; 2002 Jun; 128(2):136-41. PubMed ID: 12065914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients.
    Degboé Y; Severino-Freire M; Couture G; Apoil PA; Gaudenzio N; Hermine O; Ruyssen-Witrand A; Paul C; Laroche M; Constantin A; Livideanu CB
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1306-1312. PubMed ID: 38423295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
    Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
    Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal.
    Tanasi I; Crosera L; Taus F; Orsolini G; Adami G; Olivieri F; Bernardelli A; Bonadonna P; Nalin F; Sella S; Giannini S; Liu Y; Mannelli F; Vanderwert F; Bonifacio M; Krampera M; Rossini M; Lyons JJ; Zanotti R
    Bone; 2024 Sep; 186():117141. PubMed ID: 38823568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
    Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
    J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
    Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
    J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone lesions in systemic mastocytosis: Bone histomorphometry and histopathological mechanisms.
    Bouvard B; Pascaretti-Grizon F; Legrand E; Lavigne C; Audran M; Chappard D
    Morphologie; 2020 May; 104(345):97-108. PubMed ID: 32127247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and risk factors for fragility fracture in systemic mastocytosis.
    Degboé Y; Eischen M; Nigon D; Apoil PA; Mailhol C; Tournier E; Laurent C; Hanssens K; Hermine O; Paul C; Laroche M; Bulai-Livideanu C
    Bone; 2017 Dec; 105():219-225. PubMed ID: 28919366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
    González-de-Olano D; Alvarez-Twose I; Vega A; Orfao A; Escribano L
    Immunotherapy; 2011 May; 3(5):637-51. PubMed ID: 21554093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tryptase: A practical guide for the physician].
    Lobbes H; Reynaud Q; Mainbourg S; Lega JC; Durieu I; Durupt S
    Rev Med Interne; 2020 Nov; 41(11):748-755. PubMed ID: 32712042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome.
    Degboé Y; Eischen M; Apoil PA; Mailhol C; Dubreuil P; Hermine O; Paul C; Bulai Livideanu C; Laroche M
    Osteoporos Int; 2019 Jun; 30(6):1235-1241. PubMed ID: 30847528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
    Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
    Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
    Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
    Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
    Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP
    Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.